ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia
January 16, 2019Following an application by Silence last year, the COMP concluded that SLN124 will be of significant benefit to those affected by the chronic and potentially life-threatening condition, β-Thalassemia. -
SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia
January 16, 2019Following an application by Silence last year, the COMP concluded that SLN124 will be of significant benefit to those affected by the chronic and potentially life-threatening condition, β-Thalassemia.
Pharma Sources Insight January 2025
